Basilea Pharmaceutica Ltd (XSWX:BSLN)
CHF 43.25 0.15 (0.35%) Market Cap: 519.14 Mil Enterprise Value: 587.85 Mil PE Ratio: 68.66 PB Ratio: 0 GF Score: 69/100

Half Year 2019 Basilea Pharmaceutica AG Earnings Call Transcript

Aug 20, 2019 / 02:00PM GMT
Release Date Price: CHF39.16 (+5.90%)
Operator

Ladies and gentlemen, welcome to the Basilea Pharmaceutica's Half Year Results 2019 Conference Call and Live Webcast. I'm Sandra, the ChorusCall operator. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.

David Veitch
Basilea Pharmaceutica AG - CEO

Thank you. Hello. This is David Veitch, CEO of Basilea. I would like to welcome you all to our conference call and webcast, reviewing our financial results and key achievements for the first half year 2019 and also review our upcoming milestones and financial guidance for the full year 2019. I would like to mention that this call contains forward-looking statements.

This morning, we issued a press release and financial report on the results of the first half year 2019, and these documents are available on our website at basilea.com. Joining me today on the call are Adesh Kaul, our Chief Financial Officer; and Dr. Marc Engelhardt, our Chief Medical Officer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot